AstraZeneca, Forest Enter Superbug Combo In Late Stage Trials
October 18 2011 - 11:28AM
Dow Jones News
U.K.-based AstraZeneca PLC (AZN) and U.S. partner Forest
Laboratories Inc. (FRX) Tuesday said they plan a late-stage
clinical trial program to investigate a combination antibiotic
against superbug infections.
The two drug makers will enter ceftazidime/avibactam into five
Phase 3 trials to show the combination is an effective and
well-tolerated treatment for patients with Complicated
Intra-Abdominal Infections and Complicated Urinary Tract
Infections.
"This combination of a broad-spectrum cephalosporin and a novel
beta-lactamase inhibitor has the potential to be effective against
bacteria that would otherwise be resistant to antibiotics in
patients suffering from serious and potentially life-threatening
infections," Marco Taglietti, president of Forest Research
Institute, said in a statement.
The partners said they aimed to submit ceftazidime/avibactam for
regulatory approval in 2014.
-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292;
sten.stovall@dowjones.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024